Updates to MAPP project top interstitial cystitis/bladder pain syndrome highlights
The most informative presentations on interstitial cystitis/bladder syndrome at the 2014 AUA annual meeting will be a plenary talk by J. Quentin Clemens, MD, updating attendees on the National Institute of Diabetes and Digestive and Kidney Diseases’ Multidisciplinary Approach to Pelvic Pain project and an abstract providing long-term follow-up on the use of cyclosporine A in patients with refractory IC, according to Philip M. Hanno, MD, MPH.
This article is part of the State of Urology 2014
Dr. Hanno
The most informative presentations on interstitial cystitis/bladder syndrome (IC/BPS) at the 2014 AUA annual meeting will be a plenary talk by J. Quentin Clemens, MD, updating attendees on the National Institute of Diabetes and Digestive and Kidney Diseases’ Multidisciplinary Approach to Pelvic Pain (MAPP) project and an abstract providing long-term follow-up on the use of cyclosporine A in patients with refractory IC, according to Philip M. Hanno, MD, MPH.
“The search for the etiology of BPS and how findings might relate to treatment is the major emphasis of this AUA,” said Dr. Hanno, professor of urology at the University of Pennsylvania, Philadelphia. “In Plenary Session II, presentations regarding updates to the MAPP project (which is focusing on relationships to yield insight into pathophysiology and potential treatments), asymptomatic bacteria in urologic disease, and the role of the gastrointestinal tract in urologic disease are all potentially important in this regard.
“The session on BPS Saturday afternoon is highlighted by several presentations on etiology and other presentations on new treatments in animal models that may lead to clinical trials in the future. It appears there is much work to be done before new treatments will enter the clinical armamentarium,” Dr. Hanno added. “Until then, the treatment of BPS will continue to be more ‘art’ than ‘science.’ ”
Here's what Dr. Hanno says to watch for in the field of IC/BPS:
Plenary II, Monday, May 19 at 10:50 am: State-of-the-Art Lecture: Role of Asymptomatic Bacteriuria in Urologic Disease
David J. Klumpp, PhD
Plenary II, Monday, May 19 at 11:20 am: Update on the MAPP Project
J. Quentin Clemens, MD
PD9-10: Prospective Long-term Follow-up Study of Patients with Refractory Interstitial Cystitis treated with Cyclosporine A
Jamil Chade
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
